Identifying immune-related biomarkers to predict clinical outcomes of neoadjuvant immuno-chemotherapy (nivolumab, gemcitabine and cisplatin) in muscle-invasive bladder cancer (NCT0...

by M. Eckstein, B. Konety, C. Weight, G. Sonpavde, S. Gupta, B. Maughan, E. Gibb, E. Davicioni, M. Paari, B. Thyagarajan, A. Neeraj, S. Gupta
Published 2020-07-01

Genomic analysis of localized prostate cancer identifies AZIN1 as driver of metastatic progression

by L. Moris, T. Van Den Broeck, T. Gevaert, E. Smeets, C. Helsen, F. Handle, H. Van Poppel, W. Everaerts, D. Lambrechts, C. Buerki, E. Davicioni, S. Joniau, F. Claessens
Published 2020-07-01

Genomic ‘dark matter’ in prostate cancer: exploring the clinical utility of non-exonic ncRNA as biomarkers

by Ismael A Vergara, Nicholas eErho, Timothy J Triche, Mercedeh eGhadessi, Anamaria eCrisan, Thomas eSierocinski, Peter C Black, Christine eBuerki, Elai eDavicioni
Published 2012-02-01

Discovery of a genomic classifier for predicting clinically aggressive luminal bladder tumors with higher rates of pathological upstaging

by J.J. De Jong, Y. Liu, S.A. Boorjian, T.J. Bivalacqua, S.P. Porten, T. Wheeler, E. Davicioni, R.S. Svatek, J.L. Boormans, P.C. Black, Y. Lotan, E.A. Gibb
Published 2020-07-01

Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasiv...

by A. Necchi, D. Raggi, A. Briganti, E. Farè, P. Giannatempo, L. Marandino, A. Gallina, M. Colecchia, R. Lucianò, M. Bianchi, R. Colombo, A. Salonia, G. Gandaglia, N. Fossati, U. Capitanio, F. Montorsi, J. Boormans, Y. Liu, J. De Jong, R. Dittamore, E. Davicioni, P. Black, E. Gibb
Published 2020-07-01